Bayer Monsanto $7.25B Roundup Settlement Hearing
Analysis based on 10 articles · First reported Sep 11, 2026 · Last updated Sep 11, 2026
Approval of the $7.25 billion settlement would remove a major legal overhang that has weighed on Bayer's share price since the 2018 Bayer — Monsanto acquisition, potentially unlocking value if it caps future Roundup liabilities. A rejection or prolonged litigation would revive uncertainty over Bayer's balance sheet and could pressure the stock, while also affecting sentiment toward glyphosate-dependent agricultural chemical peers.
Bayer's Bayer — Monsanto unit appeared before the Missouri Circuit Court in St. Louis on September 14, 2026, seeking final approval of a $7.25 billion class settlement intended to resolve tens of thousands of U.S. lawsuits alleging that the Roundup weedkiller causes non-Hodgkin lymphoma. Judge Timothy Boyer examined the terms of the deal and heard objections from plaintiffs' attorneys who argue the settlement pushes claimants into a framework against their interests, as well as from lawyers who say it is the best route to compensation. Boyer is not expected to issue an immediate ruling. Bayer announced the proposed settlement in February 2026; it would cover roughly 65,000 claims in U.S. state and federal courts, with individual payouts ranging from $10,000 to $165,000 depending on disease severity, age at diagnosis, and exposure setting. The hearing followed the Eighth Circuit Court of Appeals' August 27 dismissal of objectors' attempt to move the settlement decision to federal court and Judge Boyer's rescheduling of the hearing to September 14 after a joint motion by Bayer — Monsanto and class counsel. The litigation dates to a 2015 determination by the World Health Organization's International — International Agency for Research on Cancer that glyphosate was a probable carcinogen, while the U.S. Environmental Protection Agency has consistently found glyphosate not likely to cause cancer and is working on an updated human health risk assessment expected in late 2026. In June 2026 the United States — Supreme Court of the United States ruled 7-2 that the Federal Insecticide, Fungicide, and Rodenticide Act preempts state-law failure-to-warn claims where the EPA has made a definitive safety determination, undercutting a central legal theory in thousands of pending cases. Bayer denies the allegations and says decades of studies show glyphosate is safe. The litigation has been a major overhang on Bayer since its 2018 acquisition of Bayer — Monsanto, and investors view the settlement as a key test of Chief Executive Bill Anderson's turnaround plan.
Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.
Open Dashboard